Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
NCT ID: NCT01230957
Last Updated: 2018-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
650 participants
INTERVENTIONAL
2010-10-31
2013-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objectives:
* To describe the safety profile of subjects in each of the study groups.
* To describe the immune responses elicited by toxoid A and toxoid B of subjects in each of the study groups.
Observational Objective:
* To describe the occurrence of first-time Clostridium difficile infection (CDI) episodes.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection
NCT00772343
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
NCT02052726
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
NCT03579459
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
NCT02117570
Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers
NCT00214461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be followed up for safety and immunogenicity; stool samples will also be provided in case of diarrhea.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
Clostridium difficile toxoids A and B (Low-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Group 2
Participants will receive a dose Low-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
Clostridium difficile toxoids A and B (Low-dose without adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Group 3
Participants will receive a dose High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 30, respectively.
Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Group 4
Participants will receive a dose High-dose ACAM-CDIFF™ vaccine without adjuvant on Day 0, 7, and 30, respectively.
Clostridium difficile toxoids A and B (high-dose without adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Group 5
Participants will receive a dose Placebo (0.9% normal saline) on Day 0, 7, and 30, respectively.
Placebo: 0.9% normal saline
0.5 mL, Intramuscular on Days 0, 7, and 30
Group 6
Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 7, and 180, respectively.
Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 180
Group 7
Participants will receive a dose of High-dose ACAM-CDIFF™ vaccine with adjuvant on Day 0, 30, and 180, respectively.
Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 30, and 180
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clostridium difficile toxoids A and B (Low-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Clostridium difficile toxoids A and B (Low-dose without adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Clostridium difficile toxoids A and B (high-dose without adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 30
Placebo: 0.9% normal saline
0.5 mL, Intramuscular on Days 0, 7, and 30
Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 7, and 180
Clostridium difficile toxoids A and B (high-dose with adjuvant)
0.5 mL, Intramuscular on Days 0, 30, and 180
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent form has been signed and dated
* Able to attend all scheduled visits and to comply with all trial procedures
* For a woman of childbearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination
* At risk for developing Clostridium difficile infection during the trial because of impending elective surgery or hospitalization within 60 days of enrollment, or current or impending residence in a long-term care facility or rehabilitation facility.
Exclusion Criteria
* Currently breastfeeding a child
* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
* Planned participation in another clinical trial during the present trial period
* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza (seasonal or pandemic) and pneumococcal vaccine
* Planned receipt of any vaccine in the 4 weeks following any trial vaccination, except for influenza (seasonal or pandemic) and pneumococcal vaccines
* Previous vaccination against Clostridium difficile with either the trial vaccine or another vaccine
* Current or prior Clostridium difficile infection (CDI) episode
* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
* Self-reported seropositivity for Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C
* Anticipated or current receipt of kidney dialysis treatment
* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances
* Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination
* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
* Identified as a study site employee who is involved in the protocol and may have direct access to trial-related data
* Subjects who have any history of intestinal diverticular bleeding
* Subjects who have had surgery within the past three months for gastrointestinal (GI) malignancy.
40 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi Pasteur, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Sanofi Pasteur Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Redding, California, United States
Bristol, Connecticut, United States
Stamford, Connecticut, United States
Clearwater, Florida, United States
Coral Gables, Florida, United States
Port Orange, Florida, United States
St. Petersburg, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Idaho Falls, Idaho, United States
Newton, Kansas, United States
Brockton, Massachusetts, United States
Troy, Michigan, United States
Neptune City, New Jersey, United States
Binghamton, New York, United States
Endwell, New York, United States
Cary, North Carolina, United States
Hickory, North Carolina, United States
Raleigh, North Carolina, United States
Centerville, Ohio, United States
Pittsburgh, Pennsylvania, United States
Uniontown, Pennsylvania, United States
Mt. Pleasant, South Carolina, United States
Bristol, Tennessee, United States
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
Richmond, Virginia, United States
Williamsburg, Virginia, United States
Marshfield, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
de Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, Trevino M, van Cleeff M, Foglia G, Ozol-Godfrey A, Patel DM, Pietrobon PJ, Gesser R; H-030-012 Clinical Investigator Study Team. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial. Vaccine. 2016 Apr 27;34(19):2170-8. doi: 10.1016/j.vaccine.2016.03.028. Epub 2016 Mar 21.
Small RD, Ozol-Godfrey A, Yan L. On the use of nonparametric tests for comparing immunological Reverse Cumulative distribution curves (RCDCs). Vaccine. 2019 Oct 16;37(44):6737-6742. doi: 10.1016/j.vaccine.2019.09.007. Epub 2019 Sep 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UTN: U1111-1114-3917
Identifier Type: OTHER
Identifier Source: secondary_id
H-030-012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.